> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly Once-Weekly Insulin Meets Trial Endpoints
- URL: https://www.fdaweb.com/lilly-once-weekly-insulin-meets-trial-endpoints/
- Published: 2024-05-16T12:00:00.000Z
- Updated: 2026-09-14T14:31:04.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156997

Eli Lilly says that in the QWINT-2 and QWINT-4 trials, its once-weekly insulin efsitora alfa showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally in adults with Type 2 diabetes using insulin for the first time and those who require multiple daily insulin injections. A company [statement](https://investor.lilly.com/news-releases/news-release-details/once-week-dosing-insulin-efsitora-alfa-delivers-a1c-reduction?ref=fdaweb.com) says the QWINT global clinical development program for insulin efsitora in diabetes began in 2022 and has enrolled over 4,000 people living with Type 1 or Type 2 diabetes across five global registration studies.

Efsitora alfa is described as a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is designed for once-weekly subcutaneous administration, Lilly says.